



**Note:**

- Greatest benefit is when oseltamivir is started within 48 hours of influenza illness onset, but may still be beneficial when administered >48 hours.
- **#NP** flocked swab for Rapid Flu NAT with results provided in <1 hour from receipt in the laboratory during operating hours. This test has a 94% sensitivity and 100% specificity for the detection of influenza.
- For current influenza testing hours, please see eLab Handbook. Outside testing hours, consider empiric oseltamivir for admitted patients until test results are available.

**Oseltamivir dosing for treatment of influenza:**

Children <12 months: 3 mg/kg/dose PO twice daily x 5 days

Children ≥12 months to <13 years:

- ≤15 kg: 30 mg PO twice daily x 5 days
- >15 kg to ≤23 kg: 45 mg PO twice daily x 5 days
- >23 kg to ≤40 kg: 60 mg PO twice daily x 5 days
- >40 kg: 75 mg PO twice daily x 5 days

• Adolescents ≥13 years and adults: 75 mg PO twice daily x 5 days

Dose interval and duration adjustment in renal impairment:

Patients with GFR <30 mL/min: once daily x 5 days

Patients on HD or PD: give single dose per above dosing

recommendations, then consult pharmacist for post dialysis re-dose.

**\*Risk Factors for Influenza Complications**

- Asthma or other chronic pulmonary disease
- Cardiovascular disease
- Malignancy
- Immunosuppression or immunodeficiency
- First Nations, Inuit and Métis children and youth
- Diabetes mellitus and other metabolic diseases
- Hemoglobinopathies such as sickle cell disease
- Neurological disease or neurodevelopmental disorders that compromise handling of respiratory secretions
- Chronic renal insufficiency
- Chronic liver disease
- Children or youth who reside in homes or other chronic care facilities
- Individuals <18 years of age who are on chronic acetylsalicylic acid therapy
- Obesity with BMI ≥40 kg/m<sup>2</sup>, OR a BMI ≥3 z-scores above the mean for age and gender
- Age < 2 years

**References:**

1. Allen UD, Canadian Paediatric Society, Infectious Diseases and Immunization Committee. The use of antiviral drugs for influenza: Guidance for practitioners, 2012/2013; Paediatric summary. *Pediatrics and Child Health* 2013;18(3):155-62.
2. Committee on infectious diseases. Recommendations for prevention and control of influenza in children, 2017-2018. *Pediatrics* 2017;140(4):e2017-2550.
3. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). *Morbidity & Mortality Weekly Report. Recommendations & Reports* 2011;60(1):1-24.